Haemonetics (HAE) said Tuesday it has completed the sale of its whole blood assets to GVS for $67.8 million.
The transaction includes an upfront payment of $45.3 million, with potential additional earn-outs of up to $22.5 million over four years.
The sale covers Haemonetics' entire portfolio of proprietary whole blood collection, processing, and filtration solutions, along with its Covina, California, manufacturing facility and equipment at the Tijuana, Mexico, site, the company said, adding that it will keep its Blood Center business, providing apheresis solutions for blood collection, including devices and kits.
Haemonetics said it plans to use the proceeds for general corporate purposes and further investments in growth initiatives.
Price: 80.19, Change: +0.78, Percent Change: +0.98
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.